2196 fundamentals
SHANGHAI FOSUN PHARMACEUTICAL GROUP financial statements, including revenue, expenses, and profit
The total revenue of 2196 for the last semiannual is 22.27 B HKD, and it's 0.81% higher compared to the previous semiannual. The net income of H2 24 is 1.68 B HKD.
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: HKD
TTM